<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine
Image Overlay - Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

October 12, 2020

Impel NeuroPharma Presents Data From Phase III Registration Study For The Treatment Of Acute Migraine

Impel NeuroPharma presented patient-reported outcomes data from the company's pivotal phase III, open-label study "STOP 301" of INP104 (dihydroergotamine mesylate) using the company's proprietary POD technology, for the treatment of acute migraine. Yourway is committed to supporting clinical trials for unmet medical needs.

 Back to Index
Media

Upcoming Events

GCSG 2024 US Conference

April 21-24, 2024
Naples, Florida

Precision in Clinical Trials Summit (Boston)

May 6-7, 2024
Hilton Boston Park Plaza

Media

Articles

Regulatory barriers in cross-border European pharmaceutical transport

Open chat
Come chat with us!
Hello! How can I help you?